SEARCH

SEARCH BY CITATION

References

  • 1
    Health Insurance Commission. PBS Items Expenditure, February, 2000. Available from: http:www.hic.gov.au cgi-binbroker.exe. Accessed May 26, 2002.
  • 2
    Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307314.
  • 3
    Brooks PM, Day RO. Non-steroidal anti-inflammatory drugs: differences and similarities. N Engl J Med 1991; 324: 17161725.
  • 4
    Blower AL, Brooks A, Genn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11: 283291.
  • 5
    Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol Supplement 1991; 28: 610.
  • 6
    Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 18881899.
  • 7
    Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in the risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 1996; 312: 15631566.
  • 8
    Thomas MC. Diuretics, ACE inhibitors and NSAIDs–the triple whammy. Med J Aust 2000; 172: 184185.
  • 9
    Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an under-recognised public health problem. Arch Intern Med 2000; 160: 777784.
  • 10
    Brook RD, Kramer MB, Blaxall BC, Bisognano JD. Non-steroidal anti-inflammatory drugs and hypertension. J Clin Hypertens 2000; 2: 319323.
  • 11
    Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double blind comparison. Lancet 1999; 354: 21062111.
  • 12
    Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis – A randomised controlled trial. JAMA 1999; 282: 19211928.
  • 13
    Zhao SZ, McMillen JI, Markenson JA, et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999; 19: 12691278.
  • 14
    Silverstein F, Faich GH, Golstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: a randomized controlled trial. JAMA 2000; 284: 12471255.
  • 15
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 15201528.
  • 16
    The Australian COX-2-Specific Inhibitor (CSI) Prescribing Group. Considerations for the safe prescribing and use of COX-2-specific inhibitors. Med J Aust 2002; 176: 328331.
  • 17
    National Prescribing Service. Prescribing Practice Review Sixteen. National Prescribing Service, December, 2001.
  • 18
    United States Food and Drug Administration. Available from: http:www.fda.govohrmsdocketsac01briefing3677b1−05_gi.doc. Accessed May 26 2002.
  • 19
    ADRAC report, Vol. 19, Number 2, June, 2000. Available from: http:www.health.gov.autgadocshtmlaadrbltnaadr0006.htm. Accessed May 26, 2002.
  • 20
    ADRAC report, Vol. 20, Number 1. February, 2001. Available fromL: http:www.health.gov.autgadocshtmlaadrbltnaadr0102.htm#cele. Accessed May 26, 2002.
  • 21
    Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 19291933.
  • 22
    Boyd IW, Mathew TH, Thomas MC. COX-2 inhibitors and renal failure: the triple whammy revisited. Med J Aust 2000; 173: 274.
  • 23
    Graham MG. Acute renal failure related to high-dose celecoxib. Ann Intern Med 2001; 135: 6970.
  • 24
    Jones DB. COX-2 inhibitors. Med J Aust 2001; 174: 368369.
  • 25
    Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of ‘sulfa’ allergy. Drug Safety 2001; 24: 239247.
  • 26
    Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000; 7: 159175.
  • 27
    Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 254257.
  • 28
    Boers M. NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet 2001; 357: 12221223.
  • 29
    Burnett AC, Winyard G. Clinical audit at the heart of clinical effectiveness. J Quality Clin Prac 1998; 18: 319.
  • 30
    Fraser RC, Khunti K, Baker J, Lakhani M. Effective audit in general practice: a method for systematically developing audit protocols containing evidence based review criteria. Br J Gen Pract 1997; 47: 743746.
  • 31
    Piterman L, Nelson M. Clinical audit linking continuing medical education (CME) and practice assessment (PA). Aust Fam Phys 1997; 26(Suppl 2): S91S95.
  • 32
    Cutts C, LaCaze A. Non-steroidal anti-inflammatory prescribing in a convenience sample of general practitioners. Aust Fam Physician 2002.
  • 33
    Britt H, Miller G, Valenti L.‘It's different in the bush’. A comparison of general practice activity in metropolitan and rural areas of Australia 1998–2000. AIHW Cat no. GEP, 6th edition. Canberra: Australian Institute of Health and Welfare, 2001.
  • 34
    Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology. Semin Arthritis Rheum 1997; 26: 755770.